GlassScriptPhysician profile
Nikolaos Hatzis
NPI 1700082500
$2,310.31
in general payments reported to CMS, 2019-2025
18 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2021: $14.02 · 2022: $324 · 2023: $484 · 2024: $542 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,720 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.59 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $594.22 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $271.21 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Genzyme Corporation | $240.00 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $214.49 | 2024-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.16 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $145.51 | 2019-2025 | Zerbaxa, Dificid, Capvaxive |
| Electromed, INC. | $131.21 | 2022-2024 | Smartvest |
| Baxter Healthcare | $92.35 | 2023-2024 | Hillrom - Metaneb System, Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $79.98 | 2019-2024 | Dupixent |
| Amgen INC. | $76.99 | 2022-2024 | Tezspire |
| Philips North America LLC | $59.35 | 2025 | Vest Therapy Und |
| Verona Pharma, INC. | $57.59 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $31.84 | 2023 | Inspire |
| Grifols USA, LLC | $25.95 | 2024 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $23.21 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.11 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.39 | 2023 | Hyqvia |
| Chiesi USA, INC. | $16.75 | 2024 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikolaos Hatzis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.